Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-08-09
2011-12-27
Sznaidman, Marcos (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S561000
Reexamination Certificate
active
08084447
ABSTRACT:
There is disclosed a pharmaceutical composition comprising gabapentin or an analogue thereof (pregabalin or tiagabine) and an α-aminoamide and its analgesic use. A synergistic effect of the respective analgesic activities without concomitant increase of side effects was observed.
REFERENCES:
patent: 3549690 (1970-12-01), Leigh et al.
patent: 3576864 (1971-04-01), Nagarajan
patent: 3658967 (1972-04-01), Leigh et al.
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4049663 (1977-09-01), Harper et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 4267354 (1981-05-01), Krapcho et al.
patent: 4311853 (1982-01-01), Cree et al.
patent: 4513009 (1985-04-01), Roques et al.
patent: 4602017 (1986-07-01), Sawyer et al.
patent: 4631287 (1986-12-01), Chakraborty et al.
patent: 4639468 (1987-01-01), Roncucci et al.
patent: 4725608 (1988-02-01), Nakaguchi et al.
patent: 4725619 (1988-02-01), Chakraborty et al.
patent: 4839369 (1989-06-01), Youssefyeh et al.
patent: 4894476 (1990-01-01), Butler et al.
patent: 4927835 (1990-05-01), Kise et al.
patent: 4927836 (1990-05-01), Holloway et al.
patent: 5025035 (1991-06-01), Wallace
patent: 5179109 (1993-01-01), Kamenka et al.
patent: 5236957 (1993-08-01), Dostert et al.
patent: 5256669 (1993-10-01), Askanazi et al.
patent: 5330515 (1994-07-01), Rutecki et al.
patent: 5391577 (1995-02-01), Dostert et al.
patent: 5446066 (1995-08-01), Varasi et al.
patent: 5449692 (1995-09-01), Varasi et al.
patent: 5475007 (1995-12-01), Cai et al.
patent: 5482964 (1996-01-01), Hays
patent: 5498610 (1996-03-01), Chenard
patent: 5502079 (1996-03-01), Dostert et al.
patent: 5660861 (1997-08-01), Jao et al.
patent: 5670546 (1997-09-01), Park et al.
patent: 5688830 (1997-11-01), Berger et al.
patent: 5712277 (1998-01-01), Nakamura-Craig et al.
patent: 5723489 (1998-03-01), Sher et al.
patent: 5741818 (1998-04-01), Dimmock
patent: 5849737 (1998-12-01), Chaplan et al.
patent: 5891849 (1999-04-01), Amstutz et al.
patent: 5905069 (1999-05-01), Borsook et al.
patent: 5942510 (1999-08-01), Floyd et al.
patent: 5945454 (1999-08-01), Peverello et al.
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6180624 (2001-01-01), Hill
patent: 6187338 (2001-02-01), Caruso et al.
patent: 6207685 (2001-03-01), Lallemont et al.
patent: 6242488 (2001-06-01), Bueno et al.
patent: 6281211 (2001-08-01), Cai et al.
patent: 6290986 (2001-09-01), Murdock et al.
patent: 6303819 (2001-10-01), Peverello et al.
patent: 6326374 (2001-12-01), Magnus et al.
patent: 6326385 (2001-12-01), Wickendon et al.
patent: 6372792 (2002-04-01), Chouinard
patent: 6479484 (2002-11-01), Lan et al.
patent: 6500825 (2002-12-01), Lan et al.
patent: 7091210 (2006-08-01), Lan et al.
patent: RE40259 (2008-04-01), Pevarello et al.
patent: 2004/0248978 (2004-12-01), Salvati
patent: 2006/0079570 (2006-04-01), Salvati et al.
patent: 2007/0093495 (2007-04-01), Ruggero et al.
patent: 2007/0203182 (2007-08-01), Besana et al.
patent: 2008/0096965 (2008-04-01), Barbanti et al.
patent: 198 02 237 (1999-07-01), None
patent: 0415143 (1991-06-01), None
patent: 0 525 360 (1993-02-01), None
patent: 0200101 (1996-10-01), None
patent: 1 083 164 (2001-03-01), None
patent: 1 229 332 (2002-08-01), None
patent: 2756738 (1998-12-01), None
patent: 1140748 (1969-01-01), None
patent: 2059963 (1981-04-01), None
patent: WO 98/03167 (1988-01-01), None
patent: WO 90/14334 (1990-11-01), None
patent: WO 94/22808 (1994-10-01), None
patent: WO 94/22809 (1994-10-01), None
patent: WO 96/40628 (1996-12-01), None
patent: WO 97/05102 (1997-02-01), None
patent: WO 97/05111 (1997-02-01), None
patent: WO 98/07447 (1998-02-01), None
patent: WO 98/08842 (1998-03-01), None
patent: WO 98/19674 (1998-05-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/19674 (1998-07-01), None
patent: WO 98/28255 (1998-07-01), None
patent: WO 98/43964 (1998-10-01), None
patent: WO 98/47869 (1998-10-01), None
patent: WO 99/12537 (1999-03-01), None
patent: WO 99/26614 (1999-06-01), None
patent: WO 99/35123 (1999-07-01), None
patent: WO 99/35125 (1999-07-01), None
patent: WO 99/37296 (1999-07-01), None
patent: WO 99/39712 (1999-08-01), None
patent: WO 99/44610 (1999-09-01), None
patent: WO 99/61408 (1999-12-01), None
patent: WO 00/02562 (2000-01-01), None
patent: WO 00/02592 (2000-01-01), None
patent: WO 00/53225 (2000-09-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 00/61188 (2000-10-01), None
patent: WO 0061188 (2000-10-01), None
patent: WO 01/07037 (2001-02-01), None
patent: WO 01/45684 (2001-06-01), None
patent: WO 0145684 (2001-06-01), None
patent: WO 01/98779 (2001-12-01), None
patent: WO 03/020273 (2003-03-01), None
Shailen et. al. (Expert Opinion on Drug Discovery (2006) 1:341-352).
Rosner et. al. (Clin. J. Pain (1996) 12:56-58).
Faravelli et. al. (Program No. 454.4 2000 Neuroscience Meeting Planner. New Orleans, LA: Society for neuroscience, 2000.
Chong, MS, et al, “Anticonvulsants for the management of pain”, Pain Reviews 2000, 7, pp. 129-147.
Czuczwar, Stanislaw J., “The New Generation of GABA Enhancers Potential in the Treatment of Epilepsy”, CNS Drugs 2001. pp. 339-350.
Anonymous, “Cambridge NeuroScience's grant for channel blockers,”SCRIP World Pharmaceutical News1870:8 (1993).
Anonymous, “Neurogen Licenses National Institutes of Health (NIH) anticonvulsants,”SCRIP World Pharmaceutical News1773:14 (1992).
A Wouters (ed.),Proceedings, XIVth International Symposium on Medicinal Chemistry, Maastricht, The Netherlands, Sep. 8-12, 1996, Elsevier Science B.V. (Amsterdam), (cover, front matter, table of contents, index of authors, subject index, Stanford University Libraries date stamp). Copyright 1997; date stamped Aug. 24, 1998, Swain Library, Stanford University.
Bensimon, G., et al., “A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis,”New Engl. J. Med.330:585-591 (1994).
Brown, C.M., et al., “Neuroprotective properties of Lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia,”British J. Pharmacol.115:1425-1432 (1995).
Catterall, W.A., “Common modes of drug action on Na+channels: Local anesthetics, antiarrhythmics and anticonvulsants,”Trends Pharmacol. Sci.8:57-65 (1987).
Catterall, W.A., “Neurotoxins that Act on Voltage-Sensitive Sodium Channels in Excitable Membranes,”Ann. Rev. Pharmacol. Toxicol.20:15-43 (1980).
Catterall, W.A., “Structure and Function of Voltage-Sensitive Ion Channels,”Science242:50-61 (1988).
Complaint, Civil Action No. 1:07-cv-00487 (Mar. 12, 2007).
Denicoff, K.D., et al., “Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey,”J. Clin. Psychiatry55:70-76 (1994).
Decision, Preliminary Motions, Bd.R. 125, interference No. 105,394 (2007).
Dimmock, J.R., et al., “(Aryloxy)aryl Semicarbazones and Related Compounds: A Novel Class of Anticonvulsant Agents Possessing High Activity in the Maximal Electroshock Screen,”J. Med. Chem.39:3984-3997 (1996).
Dostert et al., “New anticonvulsants with selective MAO-B inhibitory activity,”European Neuropsychopharmacology, 1(3):317-319 (Sep. 1991).
Elrifi et al., “Request for ex parte reexamination of U.S. patent No. 6,479,484 B1,” filed Jul. 2, 2003 on behalf of Newron Pharmaceuticals, SpA.
Fariello et al., “Preclinical evaluation of PNU-151774E as a novel anticonvulsant,”J. Pharmacol. Exp. Ther.285(2):397-403 (May 1998).
Fields, “Peripheral neuropathic pain: an approach to management,” in PD Wall and R Melack (eds.),Textbook of Pain, 3rded., Churchill Livingstone, pp. 991-996 (1994).
(First) Declaration of Robert A. McArthur, Pevarello Exhibit 2036, interference 105,394 (2006).
First Declaration of Stephen G. Waxman, M.D., Ph.D., PX 2003, interference No. 105,394 (2006).
Galer BS, “Neuropathic pain of peripheral origin: advances in pharmacologic treatment,”Neurol.45:S17-S25, 1995.
Guieu et al., “Central analgesic effect of valproate in patients with epilepsy,”Seizure2:
Benatti Luca
Fariello Ruggero
Maj Roberto
Salvati Patricia
Veneroni Orietta
Dechert LLP
Newron Pharmaceuticals S.p.A.
Sznaidman Marcos
LandOfFree
Pharmaceutical composition comprising gabapentin or an... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition comprising gabapentin or an..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising gabapentin or an... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4293875